Fresenius Medical Care AG/€FME

05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX

About Fresenius Medical Care AG

Fresenius Medical Care, listed under the ticker FME, is a global provider of dialysis services and products for individuals diagnosed with chronic kidney failure. Founded in 1996 and headquartered in Bad Homburg, Germany, the company operates in the healthcare sector. Beyond dialysis, Fresenius Medical Care offers a range of other services, including hospital management and related healthcare services, advancing its position as a comprehensive healthcare provider internationally.

Ticker

€FME

Primary listing

XETRA

Industry

Health Care Providers & Services

Employees

112,035

ISIN

DE0005785802

FME Metrics

BasicAdvanced
€14B
22.28
€2.11
0.85
€1.44
3.07%

What the Analysts think about FME

Analyst ratings (Buy, Hold, Sell) for Fresenius Medical Care AG stock.

Bulls say / Bears say

Fresenius Medical Care (FMC) reported stronger-than-expected first-quarter results in 2025, with revenues of €4.88 billion and adjusted operating income of €457 million, surpassing analysts' estimates. (reuters.com)
The company announced a €1 billion share buyback program and set a target to achieve a mid-teens operating income margin by 2030, indicating a strong commitment to shareholder returns and long-term profitability. (reuters.com)
FMC delivered an 18% earnings growth in 2024 and continues to accelerate momentum into 2025, demonstrating effective execution of its turnaround plan. (prnewswire.com)
In July 2024, FMC revised its expected growth in U.S. treatment volumes to flat or up to 0.5%, down from the previously expected 0.5% to 2%, due to high mortality rates among patients from COVID-19 and influenza. (reuters.com)
The company's overall operating income for the fourth quarter of 2024 decreased by 39% to €259 million, including one-off costs, despite an 8% increase in adjusted operating income. (reuters.com)
FMC's revenue slightly declined by 0.6% in 2024 compared to the previous year, indicating potential challenges in maintaining growth. (prnewswire.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jul 2025.

FME Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

FME Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy €FME

Sign up or log in to buy
Capital at risk
Extended hours trading

Upcoming events

No upcoming events
FAQs